Updated just now · Live
Stock analysis, price data, and AI-powered insights for Oragenics Inc (OGEN).
Oragenics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for OGEN.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). OGEN Stock Intelligence Report. [stoxpulse.com/stocks/ogen]
Disclaimer: The information on this page about Oragenics Inc (OGEN) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Oragenics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Oragenics Says 2 Patients And 8 Study Drug Doses A...
1d ago
Oragenics Reports 8 study drug doses in Phase IIa ...
1d ago
StoxPulse AI results for OGEN: Pulse Score 49/100. Primary sentiment trends from 2 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$3.1M
P/E Ratio
—
EPS
$-1.96
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury